Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CagriSema
- Development stage
- Phase 3
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CagriSema is a fixed-dose combination of **cagrilintide** and **semaglutide**, developed by **Novo Nordisk** for the treatment of obesity and type 2 diabetes. Semaglutide is a well-established glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion, suppresses glucagon release, and slows gastric emptying. Cagrilintide is a long-acting amylin analogue that acts as a non-selective agonist of both amylin and calcitonin receptors, contributing to increased satiety and reduced food intake. By combining these two mechanisms, CagriSema aims to achieve superior weight loss and glycemic efficacy compared to either component alone. It is currently being evaluated in the REDEFINE Phase 3 clinical trial program.
- Brand names
- CagriSema
- Other names
- cagrilintide + semaglutide
02
Targets
Beyond the preview
Go deeper on CagriSema.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CagriSema.